Lisanti Capital Growth LLC Buys 40,920 Shares of Vericel Corporation $VCEL

Lisanti Capital Growth LLC boosted its position in shares of Vericel Corporation (NASDAQ:VCEL) by 104.9% in the second quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 79,935 shares of the biotechnology company’s stock after acquiring an additional 40,920 shares during the period. Lisanti Capital Growth LLC owned 0.16% of Vericel worth $3,401,000 at the end of the most recent quarter.

A number of other hedge funds also recently bought and sold shares of the company. Ameritas Advisory Services LLC bought a new position in shares of Vericel in the second quarter worth about $30,000. CWM LLC grew its holdings in Vericel by 101.3% in the 2nd quarter. CWM LLC now owns 1,379 shares of the biotechnology company’s stock valued at $59,000 after buying an additional 694 shares during the last quarter. AlphaQuest LLC bought a new position in Vericel in the 2nd quarter worth approximately $60,000. Gagnon Securities LLC acquired a new position in shares of Vericel during the first quarter worth approximately $137,000. Finally, US Bancorp DE grew its stake in shares of Vericel by 29.9% in the first quarter. US Bancorp DE now owns 3,071 shares of the biotechnology company’s stock worth $137,000 after acquiring an additional 706 shares during the last quarter.

Vericel Stock Performance

Shares of NASDAQ VCEL opened at $38.94 on Friday. Vericel Corporation has a 52-week low of $29.24 and a 52-week high of $63.00. The stock has a market cap of $1.96 billion, a P/E ratio of 324.53 and a beta of 1.41. The firm has a 50 day moving average price of $33.78 and a 200 day moving average price of $37.72.

Vericel (NASDAQ:VCEL) last released its quarterly earnings data on Thursday, November 6th. The biotechnology company reported $0.10 EPS for the quarter, beating analysts’ consensus estimates of ($0.02) by $0.12. Vericel had a net margin of 2.85% and a return on equity of 2.47%. The business had revenue of $67.50 million during the quarter, compared to analysts’ expectations of $64.57 million. During the same quarter in the prior year, the company earned ($0.02) EPS. The firm’s quarterly revenue was up 16.6% on a year-over-year basis. Vericel has set its FY 2025 guidance at EPS. Analysts predict that Vericel Corporation will post 0.14 earnings per share for the current fiscal year.

Analyst Upgrades and Downgrades

VCEL has been the subject of several research analyst reports. Zacks Research upgraded shares of Vericel from a “hold” rating to a “strong-buy” rating in a research note on Tuesday, October 14th. Wall Street Zen upgraded Vericel from a “hold” rating to a “buy” rating in a research note on Saturday. BTIG Research downgraded Vericel from a “buy” rating to a “neutral” rating in a research report on Wednesday, September 17th. Weiss Ratings raised Vericel from a “sell (d+)” rating to a “hold (c-)” rating in a research report on Friday. Finally, Truist Financial reduced their price objective on shares of Vericel from $46.00 to $41.00 and set a “buy” rating for the company in a report on Wednesday, October 15th. One investment analyst has rated the stock with a Strong Buy rating, four have assigned a Buy rating and two have assigned a Hold rating to the stock. According to MarketBeat, the company has an average rating of “Moderate Buy” and an average price target of $58.40.

Vericel Profile

Vericel Corporation, a commercial-stage biopharmaceutical company, engages in the research, development, manufacture, and distribution of cellular therapies for sports medicine and severe burn care markets in North America. The company markets autologous cell therapy products comprising MACI, an autologous cultured chondrocytes on porcine collagen membrane for the repair of symptomatic, and single or multiple full-thickness cartilage defects of the knee; Epicel, a permanent skin replacement humanitarian use device for the treatment of adult and pediatric patients with deep-dermal or full-thickness burns; and NexoBrid, a biological orphan product for eschar removal in adults with deep partial-thickness and/or full-thickness thermal burns.